Buprenorphine

Generic Name
Buprenorphine
Brand Names
Belbuca, Brixadi, Buprenex, Buprenorphine, Butrans, Sublocade, Suboxone, Subutex, Zubsolv, Buvidal, Sixmo
Drug Type
Small Molecule
Chemical Formula
C29H41NO4
CAS Number
52485-79-7
Unique Ingredient Identifier
40D3SCR4GZ
Background

Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain. It is also commonly used as an alternative to methadone for the treatment of severe opioid addiction. Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose c...

Indication

Buprenorphine is available in different formulations, such as sublingual tablets, buccal films, transdermal films, and injections, alone or in combination with naloxone.
...

Associated Conditions
Opioid Dependence, Severe Pain, Moderate Opioid Dependence, Moderate Pain, Severe Opioid Dependence
Associated Therapies
-
Clinical Trials
Related News

Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals

First Posted Date
2010-12-17
Last Posted Date
2013-06-21
Lead Sponsor
University of Arkansas
Target Recruit Count
30
Registration Number
NCT01262092
Locations
🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain

Phase 3
Completed
Conditions
Pain
Low Back Pain
Interventions
Drug: Placebo
Drug: Buprenorphine
First Posted Date
2010-12-08
Last Posted Date
2017-02-27
Lead Sponsor
BioDelivery Sciences International
Target Recruit Count
334
Registration Number
NCT01256450
Locations
🇺🇸

Coastal Clinical Research, Inc., Mobile, Alabama, United States

🇺🇸

Alabama Orthopaedic Center - Research, Birmingham, Alabama, United States

🇺🇸

Neuro-Pain Medical Center, Fresno, California, United States

and more 21 locations

Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Buprenorphine
First Posted Date
2010-07-05
Last Posted Date
2020-01-18
Lead Sponsor
Teva Pharmaceuticals USA
Target Recruit Count
40
Registration Number
NCT01157169
Locations
🇺🇸

CEDRA Clinical Research, LLC, Austin, Texas, United States

A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals

First Posted Date
2010-06-03
Last Posted Date
2017-03-03
Lead Sponsor
Johns Hopkins University
Target Recruit Count
12
Registration Number
NCT01136356
Locations
🇺🇸

Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States

A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction

First Posted Date
2010-05-03
Last Posted Date
2018-12-31
Lead Sponsor
Titan Pharmaceuticals
Target Recruit Count
287
Registration Number
NCT01114308
Locations
🇺🇸

BPRU, Behavioral Biology Research Center, Baltimore, Maryland, United States

🇺🇸

David Geffen School of Medicine at UCLA, Los Angeles, California, United States

🇺🇸

Friends Research Institute, Torrance, California, United States

and more 17 locations

Buprenorphine for Late-Life Treatment Resistant Depression

Phase 2
Completed
Conditions
Depression
Interventions
Drug: Buprenorphine
First Posted Date
2010-02-19
Last Posted Date
2018-03-09
Lead Sponsor
University of Pittsburgh
Target Recruit Count
15
Registration Number
NCT01071538
Locations
🇺🇸

Western Psychiatric Institute and Clinica, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States

Norspan Versus Oxycontin as Postoperative Painkiller to Proximal Extracapsular Fractures of the Femur

Phase 4
Completed
Conditions
Pain, Postoperative
Interventions
Drug: Oxycodone
Drug: Buprenorphine
First Posted Date
2009-08-25
Last Posted Date
2014-12-08
Lead Sponsor
Vejle Hospital
Target Recruit Count
76
Registration Number
NCT00964808
Locations
🇩🇰

Orthopaedic Department, Vejle, Denmark

Effects of Buprenorphine on Ulnar Nerve Motor Block

Phase 4
Terminated
Conditions
Healthy Volunteers
First Posted Date
2009-07-30
Last Posted Date
2014-03-17
Lead Sponsor
University of Zurich
Target Recruit Count
20
Registration Number
NCT00949299
Locations
🇨🇭

University Hospital Zurich, Institut of Anaesthesiology, Zurich, ZH, Switzerland

A Study to Characterize the Pharmacokinetics and Tolerability of Buprenorphine Patches in Children With Moderate to Severe Mouth Pain

Phase 1
Terminated
Conditions
Chemotherapy Induced Mucositis
Mouth Pain
Interventions
Drug: Buprenorphine
First Posted Date
2009-07-28
Last Posted Date
2018-10-24
Lead Sponsor
Mundipharma Research Limited
Target Recruit Count
25
Registration Number
NCT00947466
Locations
🇬🇧

Dr Howell, Liverpool, United Kingdom

Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain

First Posted Date
2009-07-17
Last Posted Date
2017-02-27
Lead Sponsor
BioDelivery Sciences International
Target Recruit Count
153
Registration Number
NCT00941304
Locations
🇺🇸

Donald P. Bandy, DDS, San Marcos, Texas, United States

🇺🇸

Premier Research Group Limited, Salt Lake City, Utah, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy